Lancet
-
Randomized Controlled Trial Multicenter Study
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment of moderate to severe plaque psoriasis in a 12-week phase 2 study. We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis. ⋯ Celgene Corporation.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
Thrombolysis with intravenous alteplase is the only approved treatment for acute ischaemic stroke. After alteplase-induced recanalisation, reocclusion occurs in 14-34% of patients, probably because of platelet activation. Early administration of antiplatelet therapy after alteplase could reduce the risk of reocclusion and improve outcome. We compared the effects of early addition of intravenous aspirin to alteplase with standard alteplase without aspirin. ⋯ The Dutch Heart Foundation.